Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the bioequivalence of two different oral formulations of vicadrostat and empagliflozin in healthy male and female adults aged 18 to 55 years. This Phase 1, randomized, open-label, single-dose, two-period crossover trial aims to compare how these formulations are absorbed in the body when given separately or combined. Participants receive two different treatments in a crossover design vicadrostat and empagliflozin administered together then combined, or combined first then administered together. Each participant receives both treatments in separate periods, allowing comparison within the same individual. The study is conducted by Boehringer Ingelheim and includes random assignment to treatment sequences. During the study, participants undergo medical assessments including physical exams, vital signs, ECGs, and laboratory tests. Researchers measure drug concentration in plasma over up to 4 days after dosing, focusing on the area under the concentration-time curve and maximum concentration. The study involves healthy volunteers who provide informed consent and are monitored for safety throughout the trial.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the bioequivalence of Zongertinib tablets produced by two different manufacturers in healthy adult volunteers aged 18 to 50 years. The study aims to understand how the body absorbs the drug when taken as tablets under both fasting and fed conditions. This phase 1, randomized, open-label, crossover trial investigates whether the two formulations behave similarly in the body. Participants receive single oral doses of either the test product Zongertinib Formulation B or the reference product Zongertinib Formulation A in four different sequences involving both fasted and fed states. Each participant experiences all four treatment sequences in a crossover design, allowing direct comparison of the two formulations under varying conditions. During the trial, participants undergo medical evaluations including physical exams, vital signs, ECGs, and laboratory tests to ensure health status. Blood samples are collected up to 72 hours after dosing to measure drug concentration levels and absorption parameters. The primary measures include the area under the concentration-time curve and the maximum concentration of the drug in plasma. This trial involves close monitoring and lasts for the duration needed to complete all treatment sequences and assessments.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and quality of life for combining Abemaciclib with either an Aromatase Inhibitor or Fulvestrant in women with metastatic hormone receptor-positive, HER2-negative breast cancer. This Phase IV trial focuses on both pre- and postmenopausal patients receiving first-line treatment. A digital health app called CANKADO will be used to track side effects and patient-reported outcomes daily, alongside standard documentation. The study also aims to explore biomarkers to better understand treatment responses and resistance. Participants will receive either Abemaciclib combined with an Aromatase Inhibitor Anastrozole, Letrozole, or Exemestane taken orally twice daily plus daily Aromatase Inhibitor tablets every 24 hours in 28-day cycles, or Abemaciclib with Fulvestrant which is given as an injection on specific days within 28-day cycles. The two treatment groups are experimental and non-randomized, with no masking. The trial includes monitoring for side effects and quality of life throughout treatment. During the study, participants will regularly report side effects and global health status using questionnaires at multiple time points up to 24 months, including specialized breast cancer quality of life modules. Researchers will assess progression-free survival up to 48 months, as well as adverse events, hospitalizations, clinical benefit rate, overall survival, and tumor response. The use of the CANKADO app for side effect reporting is strongly recommended but not mandatory. Participants will be followed for safety and outcomes throughout the trial duration.
Actively Recruiting
Researchers are evaluating how well Fruquintinib works to treat adults with metastatic colorectal cancer who have already received standard treatments. This observational study in Germany aims to analyze patient response to Fruquintinib in routine clinical practice, focusing on survival, safety, medical care usage, and quality of life. The study also includes a translational research project to link clinical data with biomarkers for better understanding treatment benefit. Participants receive Fruquintinib as determined by their treating physician according to approved guidelines. The study collects real-world data from about 150 patients across various healthcare settings. Archival tumor tissue and blood samples are gathered to study biomarkers and circulating tumor DNA, which may indicate treatment response. During the study, participants health and treatment effects are monitored through clinical data and biomarker analysis. Researchers measure disease control, response rates, survival, adverse events, quality of life, treatment duration, hospitalizations, and other outcomes up to 33 months. The study provides insight into Fruquintinibs use and impact in everyday care over an average of 6 to 7 months of treatment and extended follow-up.
Actively Recruiting
Immune thrombocytopenia ITP is a rare blood disorder caused by an autoimmune condition that reduces platelet counts, increasing the risk of bleeding or prolonged bleeding. New treatments for ITP have emerged recently, but existing clinical studies are limited in their applicability to everyday patient care due to strict criteria. This registry aims to collect real-world clinical data and biospecimens from patients with various types of ITP to improve understanding of diagnosis, therapy, and patient outcomes in routine treatment. The registry includes patients diagnosed with primary or secondary ITP who consent to participate. Data collection occurs at defined points in the disease course either prospectively or retrospectively up to 12 months after diagnosis, provided continuous documentation is available. Biospecimens are collected and stored systematically to support research. Clinical information collected includes disease characteristics, treatment types, complications, quality of life, fatigue scores, and survival data over a follow-up period of up to 5 years. Participants provide clinical data and biosamples at enrollment, then again at 6 months and annually for up to 5 years. Assessments include platelet counts, bleeding and thromboembolic events, laboratory markers such as specific antibodies, and patient-reported outcomes like quality of life and fatigue. The study gathers epidemiological data on incidence, age, sex distribution, causes of ITP, treatment received, and remission status. The registry helps advance knowledge about ITP through long-term monitoring and standardized data collection.